Utility and impact of early t(15;17) identification by Fluorescence In Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL)

R. Kolhe, A. Mangaonkar, J. Mansour, A. Clemmons, J. Shaw, B. Dupont, L. Walczak, A. Mondal, A. Rojiani, A. Jillella, V. Kota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Acute Promyelocytic Leukemia (APL) is a curable malignancy with studies showing above 90% survival. However, population-based studies looking at survival suggest that approximately 30% of patients with APL die during induction. Early demonstration of t(15;17) will lead to accurate decision making regarding treatment. The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h). Methods: Twenty patients (15 APL cases and five non-APL cases) were selected for validating various hybridization times for the FISH probe. Expected normal signal pattern was two red and two green signals (2R2G), and the most common expected abnormal signal pattern was two fusion (yellow) signals, one red and one green (2F1R1G) and/or one fusion, one red and one green (1F1R1G). Results: The specificity of the probe ranged from 84% at 2 h, 86% at 4 h, 84% at 6 h, and 87% for overnight hybridization. The sensitivity increased from 79% at 2 h, 80% at 4 h, 81% at 6 h to 87% for overnight hybridization. Conclusion: Based on the validation studies, we recommend reading of FISH results at the 4-h incubation mark for a preliminary diagnosis and confirmation with overnight hybridization.

Original languageEnglish (US)
Pages (from-to)515-520
Number of pages6
JournalInternational Journal of Laboratory Hematology
Volume37
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Acute Promyelocytic Leukemia
Fluorescence In Situ Hybridization
Decision making
Fluorescence
Leukemia
Fusion reactions
Retinoic Acid Receptors
Survival
Validation Studies
Reading
Decision Making
Demonstrations
Population
Clinical Decision-Making
Neoplasms
Therapeutics

Keywords

  • Acute promyelocytic leukemia
  • Early diagnosis
  • Fluorescence In Situ Hybridization

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Utility and impact of early t(15;17) identification by Fluorescence In Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL). / Kolhe, R.; Mangaonkar, A.; Mansour, J.; Clemmons, A.; Shaw, J.; Dupont, B.; Walczak, L.; Mondal, A.; Rojiani, A.; Jillella, A.; Kota, V.

In: International Journal of Laboratory Hematology, Vol. 37, No. 4, 01.01.2015, p. 515-520.

Research output: Contribution to journalArticle

@article{db3e41552ccd445b821c65c9625e6704,
title = "Utility and impact of early t(15;17) identification by Fluorescence In Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL)",
abstract = "Introduction: Acute Promyelocytic Leukemia (APL) is a curable malignancy with studies showing above 90{\%} survival. However, population-based studies looking at survival suggest that approximately 30{\%} of patients with APL die during induction. Early demonstration of t(15;17) will lead to accurate decision making regarding treatment. The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h). Methods: Twenty patients (15 APL cases and five non-APL cases) were selected for validating various hybridization times for the FISH probe. Expected normal signal pattern was two red and two green signals (2R2G), and the most common expected abnormal signal pattern was two fusion (yellow) signals, one red and one green (2F1R1G) and/or one fusion, one red and one green (1F1R1G). Results: The specificity of the probe ranged from 84{\%} at 2 h, 86{\%} at 4 h, 84{\%} at 6 h, and 87{\%} for overnight hybridization. The sensitivity increased from 79{\%} at 2 h, 80{\%} at 4 h, 81{\%} at 6 h to 87{\%} for overnight hybridization. Conclusion: Based on the validation studies, we recommend reading of FISH results at the 4-h incubation mark for a preliminary diagnosis and confirmation with overnight hybridization.",
keywords = "Acute promyelocytic leukemia, Early diagnosis, Fluorescence In Situ Hybridization",
author = "R. Kolhe and A. Mangaonkar and J. Mansour and A. Clemmons and J. Shaw and B. Dupont and L. Walczak and A. Mondal and A. Rojiani and A. Jillella and V. Kota",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/ijlh.12326",
language = "English (US)",
volume = "37",
pages = "515--520",
journal = "International Journal of Laboratory Hematology",
issn = "1751-5521",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Utility and impact of early t(15;17) identification by Fluorescence In Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL)

AU - Kolhe, R.

AU - Mangaonkar, A.

AU - Mansour, J.

AU - Clemmons, A.

AU - Shaw, J.

AU - Dupont, B.

AU - Walczak, L.

AU - Mondal, A.

AU - Rojiani, A.

AU - Jillella, A.

AU - Kota, V.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Acute Promyelocytic Leukemia (APL) is a curable malignancy with studies showing above 90% survival. However, population-based studies looking at survival suggest that approximately 30% of patients with APL die during induction. Early demonstration of t(15;17) will lead to accurate decision making regarding treatment. The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h). Methods: Twenty patients (15 APL cases and five non-APL cases) were selected for validating various hybridization times for the FISH probe. Expected normal signal pattern was two red and two green signals (2R2G), and the most common expected abnormal signal pattern was two fusion (yellow) signals, one red and one green (2F1R1G) and/or one fusion, one red and one green (1F1R1G). Results: The specificity of the probe ranged from 84% at 2 h, 86% at 4 h, 84% at 6 h, and 87% for overnight hybridization. The sensitivity increased from 79% at 2 h, 80% at 4 h, 81% at 6 h to 87% for overnight hybridization. Conclusion: Based on the validation studies, we recommend reading of FISH results at the 4-h incubation mark for a preliminary diagnosis and confirmation with overnight hybridization.

AB - Introduction: Acute Promyelocytic Leukemia (APL) is a curable malignancy with studies showing above 90% survival. However, population-based studies looking at survival suggest that approximately 30% of patients with APL die during induction. Early demonstration of t(15;17) will lead to accurate decision making regarding treatment. The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h). Methods: Twenty patients (15 APL cases and five non-APL cases) were selected for validating various hybridization times for the FISH probe. Expected normal signal pattern was two red and two green signals (2R2G), and the most common expected abnormal signal pattern was two fusion (yellow) signals, one red and one green (2F1R1G) and/or one fusion, one red and one green (1F1R1G). Results: The specificity of the probe ranged from 84% at 2 h, 86% at 4 h, 84% at 6 h, and 87% for overnight hybridization. The sensitivity increased from 79% at 2 h, 80% at 4 h, 81% at 6 h to 87% for overnight hybridization. Conclusion: Based on the validation studies, we recommend reading of FISH results at the 4-h incubation mark for a preliminary diagnosis and confirmation with overnight hybridization.

KW - Acute promyelocytic leukemia

KW - Early diagnosis

KW - Fluorescence In Situ Hybridization

UR - http://www.scopus.com/inward/record.url?scp=84948098602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948098602&partnerID=8YFLogxK

U2 - 10.1111/ijlh.12326

DO - 10.1111/ijlh.12326

M3 - Article

C2 - 25639817

AN - SCOPUS:84948098602

VL - 37

SP - 515

EP - 520

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

SN - 1751-5521

IS - 4

ER -